Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Summary

Adult patients with small-cell lung cancer (SCLC) will be treated with nivatrotamab a monoclonal anti GD2×CD3 bispecific antibody to investigate the safety and tolerability of the drug.

Timeline

Start

2021-08-17

Primary completion

2022-04-08

Completion

2022-04-08

Outcome

Outcome not reported

Stopped (Business): “Study terminated due to business priorities”

Drugs

Indications